155 related articles for article (PubMed ID: 35392934)
1. Correlation between changes of pelvic bone marrow fat content and hematological toxicity in concurrent chemoradiotherapy for cervical cancer.
Wang C; Qin X; Gong G; Wang L; Su Y; Yin Y
Radiat Oncol; 2022 Apr; 17(1):70. PubMed ID: 35392934
[TBL] [Abstract][Full Text] [Related]
2. Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer.
Qin X; Wang C; Gong G; Wang L; Su Y; Yin Y
BMC Cancer; 2022 Nov; 22(1):1149. PubMed ID: 36348290
[TBL] [Abstract][Full Text] [Related]
3. Fat composition changes in bone marrow during chemotherapy and radiation therapy.
Carmona R; Pritz J; Bydder M; Gulaya S; Zhu H; Williamson CW; Welch CS; Vaida F; Bydder G; Mell LK
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):155-63. PubMed ID: 25015207
[TBL] [Abstract][Full Text] [Related]
4. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
[TBL] [Abstract][Full Text] [Related]
5. Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC.
Chang Y; Yang ZY; Li GL; Li Q; Yang Q; Fan JQ; Zhao YC; Song YQ; Wu G
Int J Gynecol Cancer; 2016 May; 26(4):770-6. PubMed ID: 26844613
[TBL] [Abstract][Full Text] [Related]
6. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
Huang J; Gu F; Ji T; Zhao J; Li G
Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
[TBL] [Abstract][Full Text] [Related]
7. The relationship between the radiation dose of pelvic-bone marrow and lymphocytic toxicity in concurrent chemoradiotherapy for cervical cancer.
Zhang BZ; Li Y; Xu LM; Chai YL; Qu C; Cao YJ; Wang J; Hou HL; Zhang J
Radiat Oncol; 2023 Jan; 18(1):12. PubMed ID: 36658595
[TBL] [Abstract][Full Text] [Related]
8. The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy.
Chen M; Wang D; Bao Z; Yi Z; Mei Z; Sun S; Xiang Q; Yang C; Yang H; Qiu H; Xie C
Radiat Oncol; 2023 Apr; 18(1):66. PubMed ID: 37031167
[TBL] [Abstract][Full Text] [Related]
9. Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients.
Franco P; Arcadipane F; Ragona R; Lesca A; Gallio E; Mistrangelo M; Cassoni P; Arena V; Bustreo S; Faletti R; Rondi N; Morino M; Ricardi U
Med Oncol; 2016 Jul; 33(7):72. PubMed ID: 27277756
[TBL] [Abstract][Full Text] [Related]
10. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric parameters and absolute monocyte count can predict the prognosis of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemotherapy and volumetric-modulated arc therapy.
Xiang X; Ding Z; Zeng Q; Feng L; Qiu C; Chen D; Lu J; Li N
Radiat Oncol; 2022 Mar; 17(1):48. PubMed ID: 35248087
[TBL] [Abstract][Full Text] [Related]
12. Correlation between radiation dose to ¹⁸F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
Rose BS; Liang Y; Lau SK; Jensen LG; Yashar CM; Hoh CK; Mell LK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1185-91. PubMed ID: 22270171
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
[TBL] [Abstract][Full Text] [Related]
14. A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer.
Chen H; Zhong Q; Liu Y; Li J; Deng W; Wang J; Zhou S; Yu Z; Huang X; Huang Y; Zhen B; Wei J; Zhang W; Ruan X; Xiao L
Radiat Oncol; 2023 Nov; 18(1):193. PubMed ID: 38012675
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.
Mahantshetty U; Krishnatry R; Chaudhari S; Kanaujia A; Engineer R; Chopra S; Shrivastava S
Int J Gynecol Cancer; 2012 Oct; 22(8):1427-34. PubMed ID: 22932264
[TBL] [Abstract][Full Text] [Related]
16. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
[TBL] [Abstract][Full Text] [Related]
17. Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
Lee AY; Golden DW; Bazan JG; Kopec M; Pelizzari CA; Aggarwal S; Chang DT; Liauw SL
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):306-312. PubMed ID: 28068238
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal study of acute haematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
Zhu H; Zakeri K; Vaida F; Carmona R; Dadachanji KK; Bair R; Aydogan B; Hasan Y; Yashar CM; Mell LK
J Med Imaging Radiat Oncol; 2015 Jun; 59(3):386-93; quiz 394. PubMed ID: 25828068
[TBL] [Abstract][Full Text] [Related]
19. A prospective phase II study of magnetic resonance imaging guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy with concurrent chemotherapy for rectal cancer.
Jianyang W; Yuan T; Yuan T; Xin W; Ning L; Hua R; Hui F; Yanru F; Shulian W; Yongwen S; Yueping L; Weihu W; Yexiong L; Jing J
Radiol Med; 2016 Apr; 121(4):308-14. PubMed ID: 26612321
[TBL] [Abstract][Full Text] [Related]
20. Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy.
Yang TJ; Oh JH; Apte A; Son CH; Deasy JO; Goodman KA
Radiother Oncol; 2014 Oct; 113(1):29-34. PubMed ID: 25304718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
